Drotrecogin alfa (activated) in severe sepsis: A systematic review and new cost-effectiveness analysis

被引：15

作者：

Costa V. ^{[1
]}

Brophy J.M. ^{[1
,2
]}

机构：

[1] Technology Assessment Unit, McGill University Health Centre, Montreal, QC

[2] Department of Medicine, McGill University Health Centre, Montreal, QC

来源：

BMC Anesthesiology | / 7卷 / 1期

关键词：

Severe Sepsis; Drotrecogin Alfa; Approval Vote; Severe Sepsis Patient; Life Year Gain;

D O I：

10.1186/1471-2253-7-5

中图分类号：

学科分类号：

摘要：

Background: Activated drotrecogin alfa (human activated protein C, rhAPC), is produced by recombinant DNA technology, and purports to improve clinical outcomes by counteracting the inflammatory and thrombotic consequences of severe sepsis. Controversy exists around the clinical benefits of this drug and an updated economic study that considers this variability is needed. Methods: A systematic literature review was performed using Medline, Embase and the International Network of Agencies for Health Technology Assessment (INAHTA) databases to determine efficacy, safety and previous economic studies. Our economic model was populated with systematic estimates of these parameters and with population life tables for longer term survival information. Monte Carlo simulations were used to estimate the incremental cost-effectiveness ratios (ICERs) and variance for the decision analytic models. Results: Two randomized clinical trials (RCTS) of drotrecogin alfa in adults with severe sepsis and 8 previous economic studies were identified. Although associated with statistical heterogeneity, a pooled analysis of the RCTs did not show a statistically significant 28-day mortality benefit for drotrecogin alfa compared to placebo either for all patients (RR: 0.93, 95% CI: 0.69, 1.26) or those at highest risk as measured by APACHE II ≥ 25 (RR: 0.90, 95% CI: 0.54, 1.49). Our economic analysis based on the totality of the available clinical evidence suggests that the cost-effectiveness of drotrecogin alfa is uncertain (< 59% probability that incremental cost-effectiveness ratio (ICER) life year gained (LYG) ≤ $50,000/LYG) when applied to all patients with severe sepsis. The economic attractiveness of this therapy improves when administered to those at highest risk as assessed by APACHE II ≥ 25 (93% probability ICER ≤ $50,000/ LYG) but these results are not robust to different measures of disease severity. Conclusion: The evidence supporting the clinical and economic attractiveness of drotrecogin alfa is not conclusive and further research appears to be indicated. © 2007 Costa and Brophy; licensee BioMed Central Ltd.

引用

共 59 条

[1]

Lyseng-Williamson K.A., Perry C.M., Drotrecogin alfa (activated), Drugs, 62, pp. 617-630, (2002)

[2]

FDA Clinical Review. Drotrecogin Alfa (Activated), (2006)

[3]

Drotrecogin Alfa (Activated) Letter of Approval, (2006)

[4]

Xigris Product Information

[5]

Notice of Compliance - Xigris - 31-01-2003, (2006)

[6]

Mackenzie A.F., Activated protein C: Do more survive?, Intensive Care Med, 31, pp. 1624-1626, (2005)

[7]

Smith B., Drotrecogin alfa: Too early to give it early, Emerg Med Australas, 17, pp. 179-180, (2005)

[8]

Angus D.C., Laterre P.F., Helterbrand J., Ely E.W., Ball D.E., Garg R., Weissfeld L.A., Bernard G.R., The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis, Crit Care Med, 32, pp. 2199-2206, (2004)

[9]

Drabinski A., Williams G., Formica C., Observational evaluation of health state utilities among a cohort of sepsis patients, Value in Health, 4, pp. 128-129, (2001)

[10]

Baltussen R.M.P.M., Hutubessy R.C.W., Evans D.B., Murray C.J.M., Uncertainty in cost-effectiveness analysis, International Journal of Technology Assessment in Health Care, 18, pp. 112-119, (2002)

← 1 2 3 4 5 6 →